Retrospective analysis of oral medication treatment in adult patients with Kashin-Beck disease
10.3760/cma.j.cn231583-20210415-00123
- VernacularTitle:成人大骨节病患者口服药物治疗情况回顾性分析
- Author:
Zhe JIAO
1
;
Junrui PEI
;
Silu CUI
;
Hui LIU
;
Jun YU
Author Information
1. 哈尔滨医科大学中国疾病预防控制中心地方病控制中心大骨节病防治研究所 150081
- Keywords:
Kashin-Beck disease;
Adult;
Oral medication;
Retrospective analysis
- From:
Chinese Journal of Endemiology
2021;40(10):839-844
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the oral medication treatment of adult patients with Kashin-Beck disease(KBD) in China, so as to provide theoretical basis for medication screening of KBD and to provide scientific guidance for clinical treatment of KBD.Methods:Based on the "Endemic Disease Prevention and Control Project of Special Funds for Local Public Health Subsidized by the Central Government" and "Major Public Health Service Endemic Disease Prevention and Control Project", the treatment information of adult patients with KBD in 11 provinces (autonomous regions, referred to as provinces) in China from 2006 to 2017 was collected, and the treatment coverage of adult patients with KBD in different years and regions was analyzed, and the curative effect of patients with different severity was evaluated.Results:From 2006 to 2017, the number of provinces participating in the treatment project was from 2 to 11. The actual total number of people treated in China was 68 061, with a completion rate of 78.10% (68 061/87 149); the annual number of people treated increased linearly; the overall clinical symptom remission rates of adult patients with KBD in all regions reached more than 50%, and the overall treatment effect showed an upward trend year by year; compared with patients with grade Ⅲ, after oral medication, the remission rates of clinical symptoms in patients with gradeⅠandⅡ were higher (the average remission rate of clinical symptoms was 84.13% for gradeⅠ, 80.71% for grade Ⅱ and 72.11% for grade Ⅲ, P < 0.05). Conclusions:Oral medication treatment can effectively alleviate the clinical symptoms of most adult patients with KBD of grade Ⅰ and Ⅱ. Patients of grade Ⅲ should be considered treating with oral medication combined with other treatment methods. A considerable number of patients are still ineffective in taking drugs at this stage, and it is urgent to carry out the screening, research and development of specific medications for KBD.
